Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Montpelier Re Holdings Ltd. ( MRH - Analyst Report ) expects fourth quarter 2012 pretax loss from Superstorm Sandy to approximate $95 million, net of reinsurance recoveries and reinstatement premiums.
The company posted strong results in each of the three quarters in 2012 aided by lower catastrophe activities. However, cat loss stemming from Sandy might alter the picture in the final quarter. Loss modeling companies project the amount to be approximately $20–$22 billion.
The Zacks Consensus Estimate for the fourth quarter and full year 2012 are currently pegged at a loss of 31 cents and earnings of $2.45. While fourth quarter estimates represents a year-over-year decline of 13.6%, full year estimate translates into a year- over-year improvement of nearly 198%.
Each of the three reported quarters exhibited huge improvement in underwriting results, posting underwriting profit, rebounding from underwriting loss incurred in each of the three quarters in 2011. Combined ratio also exhibited huge year-over-year improvement.
Another property and casualty insurer, ACE Limited ( ACE - Analyst Report ) expects loss from Superstorm Sandy to approximate $380 million after tax, net of reinsurance and including reinstatement premiums in the fourth quarter of 2012.
Concurrently, it revised its full year 2012 earnings expectation to $7.43 to $7.53 per share. The guidance is lowered from the prior expectation of $7.73–$8.03 per share to accommodate the higher-than-expected catastrophe loss.
We believe Montpelier is well positioned to deliver solid numbers going forward, given its increased exposure in the property catastrophe lines of business. Also, focusing on underwriting operations, augmenting capital flexibility, and strengthening its competitive position augur well going forward. We retain our Neutral recommendation on Montpelier.
Montpelier and ACE Limited, both carry a Zacks #3 Rank, translating into a short-term Hold rating.
Read the full Analyst Report on ACE
Read the full Analyst Report on MRH